Status:
TERMINATED
Predictors of Lorcaserin-Induced Weight Loss
Lead Sponsor:
Columbia University
Collaborating Sponsors:
New York State Psychiatric Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Overweight and Obesity
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
This two-phase study aims to explore ways to predict who will respond well to the weight loss drug lorcaserin and to understand the mechanisms that develop which limit drug efficacy. Subjects will be ...
Detailed Description
In phase 1, at Weeks 1 and 5, participants will take the weight loss drug lorcaserin or placebo for 7 days. At Week 5 participants will receive whichever treatment they did not receive at Week 1. At t...
Eligibility Criteria
Inclusion
- Body Mass Index (BMI) 28-40
Exclusion
- Any clinically significant or relevant medical condition, including:
- Diabetes
- Uncontrolled Hypertension
- Heart disease
- Bleeding disorder
- Kidney or liver dysfunction
- Neurologic disease
- Psychiatric or eating disorders
- Pregnancy or breastfeeding
- Use of tobacco or opiates
- History of alcohol or drug abuse
- Recent weight change +/- 5%
- Medications that affect body weight
Key Trial Info
Start Date :
January 3 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 14 2020
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT03353220
Start Date
January 3 2018
End Date
February 14 2020
Last Update
March 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Medical Center
New York, New York, United States, 10032